The proportion of patients who achieved at least 90% improvement from baseline in PASI after 16 weeks of treatment was 35% higher for risankizumab compared with adalimumab, showing that inhibiting the IL-23p19 pathway has set a new therapeutic benchmark.
Investigators found a number of benefits to subcutaneous methotrexate vs oral methotrexate for treatment and prophylaxis of chronic plaque psoriasis.
A greater proportion of patients with moderate to severe plaque psoriasis achieved complete skin clearance with ixekizumab when compared with guselkumab, according to results from a phase 4 head-to-head study.
According to results from the ECLIPSE trial, treatment with guselkumab was found to be superior to secukinumab in adult patients with moderate-to-severe plaque psoriasis based on 90% or better improvement in patients’ Psoriasis Area and Severity Index score compared to baseline (PASI 90 response).
The FDA has expanded the approval for Taclonex Topical Suspension and Enstilar Foam, two plaque psoriasis therapies to include younger patients.
A clinical guideline for the use of phototherapy for the care and management of adult patients with psoriasis developed by the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) has been published.
Addition of apremilast to a regimen of topical corticosteroids was safe and effective in patients with moderate plaque-type psoriasis.
A fixed-dose combination lotion comprised of halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) is more effective for treating moderate-to-severe plaque psoriasis than either component alone.
Researchers completed 2 post hoc analyses of large, double-blind trials examining the efficacy of HP/TAZ combination therapy for clinically meaningful outcomes.
The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.
